search

All clinical trials

Results 4551-4560 of 470744

NTS-WBRT VS HA-WBRT in Brain Metastases

Brain Metastases

This research is being done to compare quality of life and symptom burden in participants who receive two different types of radiation therapy (normal tissue sparing whole brain radiation therapy (NTS-WBRT) or standard of care hippocampal avoidance whole brain radiation Therapy (HA-WBRT). This research study involves: NTS-WBRT (normal tissue sparing whole brain radiation therapy) HA-WBRT (hippocampal avoidance whole brain radiation Therapy) Memantine standard of care drug

Recruiting20 enrollment criteria

Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes

DiabetesDiabetes Type 26 more

This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.

Recruiting65 enrollment criteria

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Acute Myeloid Leukemia

The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with Acute Myeloid Leukemia (AML).

Recruiting17 enrollment criteria

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases...

Non Small Cell Lung CancerBrain Metastases2 more

This is an open-label, non-randomised, phase II, multicenter clinical trial. 71 stage IV or recurrent, non-small cell lung cancer patients with synchronous brain metastases will be enrolled in this trial to evaluate the efficacy of Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment.

Recruiting34 enrollment criteria

TVMR With the Innovalve System Trial - Pilot Study in Italy

Mitral Valve Regurgitation (Degenerative or Functional)

Study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Recruiting6 enrollment criteria

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate...

Metastatic Castration-resistant Prostate CancerProstate Cancer

This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abiraterone. FOR46 is designed to target and bind to CD46, a transmembrane cellular protein expressed at moderate or high levels in numerous cancer types. The investigators hypothesize that the combination of FOR46 plus enzalutamide will achieve a clinically significant composite response rate with sufficient durability of response in mCRPC patients.

Recruiting44 enrollment criteria

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel...

Recurrent Platinum-resistant Ovarian Cancer

A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405 subjects will be enrolled.

Recruiting44 enrollment criteria

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)...

NMO Spectrum Disorder

The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.

Recruiting21 enrollment criteria

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled...

Schizophrenia

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score. The secondary objectives of the study are to evaluate the efficacy of adjunctive KarXT compared with placebo on the Personal and Social Performance Scale (PSP), improvement in disease severity and symptoms, safety and tolerability, and pharmacokinetics.

Recruiting50 enrollment criteria

n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy

Diabetic Neuropathies

Sensorimotor neuropathy (SMN) and cardiovascular autonomic neuropathy (CAN) are the most common complications of type 2 diabetes (T2D). SMN affects ~30% of people with T2D and CAN ~20%. SMN causes pain, impairs and limits physical activity, and increases the risk for physical disability, complications (such as foot ulcerations), and premature mortality. Moreover, both motor and sensory nerve function are important regulators of muscle function; impaired myofiber innervation causes myofiber loss, muscle fat infiltration, and increases the risk of age-associated sarcopenia and falls. CAN often goes unrecognized because it presents with non-specific symptoms, such as resting tachycardia and fixed heart rate, exercise intolerance, and orthostatic hypotension. However, CAN is a serious problem because it increases the risk for cardiovascular events and mortality several-fold. Both SMN and CAN have long been considered a consequence of T2D, but it is now becoming clear that they precede the diagnosis of T2D and are already detectable in people with prediabetes, especially those with impaired glucose tolerance. Treatments for both SMN and CAN focus on symptom management because there are no effective therapeutics that target the underlying neuropathy. The results from studies conducted in animal models suggest fish oil-derived n-3 polyunsaturated fatty acids (n-3 PUFA) may have therapeutic effects for people with SMN and CAN. The purpose of this proposal is to conduct a randomized controlled trial to test the hypothesis that dietary supplementation with fish oil-derived n-3 PUFA improves sensorimotor and cardiovascular autonomic functions in people with impaired glucose tolerance. Forty 55-80 year old men and women with impaired glucose tolerance (plasma glucose 2 h after a 75 g glucose challenge ≥140 mg/dl) and evidence of SMN (assessed as epidermal nerve fiber density) will be randomized to either receive fish oil-derived n-3 PUFA (4.2 g per day; n=20) or placebo (n=20) for six months. Sensorimotor and cardiovascular autonomic function will be evaluated after three and 6 months of the interventions.

Recruiting12 enrollment criteria
1...455456457...47075